Phase 1, Open-label, Drug-drug Interaction Study to Assess Effect Between Radiprodil and the Co-administered Drugs.

NCT ID: NCT06975605

Last Updated: 2025-11-18

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 18 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-05-20
• Study Completion Date: 2025-07-10

Brief Summary

This is a Phase 1, open-label, 3-period study to determine radiprodil's potential to act as a perpetrator of cytochrome P-450 (CYP) metabolic pathways and transporter pathways. The study will evaluate the pharmacokinetics (PK) and safety effects of co-administration of radiprodil with oral midazolam, rosuvastatin, warfarin, digoxin, and omeprazole in healthy adult subjects. The study will be conducted in 1 cohort of healthy adult participants only.

Detailed Description

This is a Phase 1, open-label, 3-period study to evaluate the PK and safety effects of co-administration of radiprodil with oral midazolam, rosuvastatin, warfarin, digoxin, and omeprazole in healthy adult subjects. The study will be conducted at a single site.

The study will be conducted in 1 cohort of participantsUp to 18 male or female healthy adults are planned to be recruited in this study. Participants will be required to be in the study for up to 80 days, which includes a 27-day screening period, 24-day confinement period, and a follow-up phone call 30 days (± 2 days) after the last dose of study drug. Study drugs will be administered using a sequential cocktail approach consisting of substrates of multiple CYP enzymes or transporters.

Conditions

Tuberous Sclerosis Complex (TSC); Focal Cortical Dysplasia; Other Neurological Disorders

Study Design

• Allocation Method: NA
• Intervention Model: SEQUENTIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Experimental Cohort

Study Drug - Radiprodil will be administred using a sequential cocktail approach consisting of substrates of multipleCYP enzymes or transporters.

Group Type: EXPERIMENTAL

Radiprodil + co-administered drugs

Intervention Type: DRUG

Study drug radiprodil will be administered asbelow in a sequential manner.

• Radiprodil 7.5 mg, 15 mg and 30 mg will be administered in a sequential manner.

Co-administered drugs include: - Warfarin - 10 mg tablets, midazolam 1 mg, digoxin 0.25 mg, rosuvastatin 10 mg, omeprazole 20 mg, Vitamin K - 10 mg.

Interventions

Radiprodil + co-administered drugs

Study drug radiprodil will be administered asbelow in a sequential manner.

• Radiprodil 7.5 mg, 15 mg and 30 mg will be administered in a sequential manner.

Co-administered drugs include: - Warfarin - 10 mg tablets, midazolam 1 mg, digoxin 0.25 mg, rosuvastatin 10 mg, omeprazole 20 mg, Vitamin K - 10 mg.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Body mass index (BMI) between 18 and 32 kg/m2 (inclusive) and weighs at least 50 kg at Screening.
• Female participants must be non-lactating and of non-child-bearing potential.
• Male participants if engaging in sexual intercourse with a female partner who could become pregnant must agree to use adequate contraception.
• Participant is of Caucasian origin (note: people of Filipino, Chinese, Japanese, Korean, Vietnamese or Asian-Indian origin are excluded due to higher exposure following rosuvastatin administration).
• Ability to provide signed informed consent and to understand and comply with the requirements of the study including dietary requirements and requirement to stay confined on site for the duration of the study

Exclusion Criteria

• History of contraindications or hypersensitivity to radiprodil or any components of the formulations or history of hypersensitivity to warfarin, midazolam, digoxin, rosuvastatin, omeprazole, or vitamin K.
• Female participants who are pregnant, breastfeeding, or have a positive pregnancy test at Screening.
• History or presence of significant (in the opinion of the PI) cardiovascular, pulmonary, hepatic, renal, hematological, gastrointestinal, endocrine, immunologic, dermatologic, urologic, neurological, malignancy, psychiatric disease, or brain surgery or injury.
• Any surgical or medical condition that, in the opinion of the PI, could interfere with the absorption, distribution, metabolism, or excretion of the drug.
• History of any CS allergic conditions (including drug allergies, asthma, eczema, or anaphylactic reactions, but excluding untreated, asymptomatic seasonal allergies at time of dosing on Day 1).
• History of illicit drug abuse or alcohol abuse use within 2 years of Screening.
• History of suicide attempts or deliberate self-harm, or a score of 4 or 5 on ideation or any suicidal behavior on the C-SSRS.
• Routine consumption of more than 2 units of alcoholic beverages per day or more than 14 units per week (a unit of alcohol is equivalent to 1 can of beer, 1 glass of wine, or the equivalent of 1 alcoholic drink).
• Routine consumption of an average of more than five (5) 240 mL servings of coffee or other caffeinated beverages per day.
• A positive test result for amphetamines, barbiturates, benzodiazepines, cocaine, methadone, methamphetamines, opiates, methylenedioxymethamphetamine, phencyclidine, tetrahydrocannabinol, cotinine, or alcohol at Screening or Day -1.
• Use of marijuana (including prescribed marijuana) within 30 days of Day -1.
• Use of tobacco-containing products and nicotine or nicotine containing products in the 2 months prior to Day 1.
• Use of any IP and prescription drug within 30 days of Day -1 or within 5 half-lives whichever is longer.
• Use of any over-the-counter (OTC) medication, including herbal products within the 14 days or 5 half-lives prior to dosing, whichever is longer.
• Any vaccine within 7 days of Day -1.
• Acute illness within 14 days of study Day 1.
• Surgery within the past 90 days prior to Day 1.
• Any CS ECG abnormality at Screening.
• Received an IP in any clinical trial within 30 days of Day -1.
• Women of childbearing potential using oral, injected or implanted hormonal contraception.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 55 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Avance Clinical Pty Ltd.

INDUSTRY

Sponsor Role: collaborator

GRIN Therapeutics, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Nucleus Network Melbourne

Melbourne, Victoria, Australia

Countries

Australia

Other Identifiers

RAD-GRIN-506

Identifier Type: -

Identifier Source: org_study_id